A recent study published in npj Gut and Liver has shown that semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is associated with significant improvements in liver health among patients with pre-existing liver disease. The real-world study found that semaglutide reduced liver stiffness and lowered the risk of steatohepatitis alcoholic liver disease and all-cause mortality, suggesting that its benefits extend well beyond weight loss and glucose control.
Semaglutide mimics the naturally occurring GLP-1 hormone released after meals by stimulating insulin secretion suppressing glucagon release delaying gastric emptying and reducing appetite through actions in the central nervous system (CNS). While these effects are well known for improving blood glucose levels and promoting weight loss, growing evidence suggests that semaglutide also exerts direct protective effects on organs such as the liver.
Venkatakrishnan et al. analyzed electronic health records from 6,734 semaglutide-treated patients with pre-existing liver disease and found that higher attained doses of semaglutide were associated with lower risks of all-cause mortality steatohepatitis and alcoholic liver disease. Greater weight loss was also linked to lower risks of steatohepatitis steatotic liver disease and hepatorenal syndrome. In a separate analysis of 326 adults who underwent repeated liver elastography, median liver stiffness significantly declined following semaglutide treatment. Nearly 60% of patients experienced reduced liver stiffness more than 40% achieved a clinically meaningful reduction of at least 20% and approximately one-fifth improved to a lower fibrosis stage. Patients with the most advanced liver fibrosis experienced the greatest improvements. Changes in liver stiffness showed little correlation with changes in body weight BMI blood glucose or liver enzyme levels, suggesting that semaglutide may exert direct hepatoprotective effects beyond its metabolic actions.
These findings are consistent with previous studies demonstrating that semaglutide provides protection across multiple organ systems. Colhoun et al. reported that semaglutide reduced the progression of chronic kidney disease in patients with overweight or obesity and cardiovascular disease while the landmark SELECT trial by Lincoff et al. showed that once-weekly semaglutide reduced the risk of heart attack stroke and cardiovascular death by 20% in adults with overweight or obesity and established cardiovascular disease even when weight loss alone could not fully explain the benefit. Together these studies suggest that semaglutide acts through multiple biological pathways involving inflammation vascular function metabolism and organ protection.
The study highlights that semaglutide is emerging as more than a treatment for obesity or type 2 diabetes. Alongside its established cardiovascular and kidney benefits the latest real-world evidence indicates that it may also improve liver health by slowing disease progression and reducing fibrosis. Although further randomized clinical trials are needed to confirm these findings the growing body of evidence suggests that semaglutide may become an important multi-organ protective therapy for patients with metabolic disease.
References
- Venkatakrishnan AJ, Purushotham K, Varma G, Aman A, Murugadoss K, Soundararajan V. Semaglutide is associated with stiffness improvement and broad liver benefits with distinct dose- and weight-linked patterns. npj Gut Liver. 2026 Aug 3;3(1):28.
- Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024 Jul;30(7):2058–66. doi:10.1038/s41591-024-03015-5 PubMed PMID: 38796653; PubMed Central PMCID: PMC11271413.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023 Dec 13;389(24):2221–32.